Loading...
•
Mar 31, 2020
BioCryst Q1 2020 Earnings Report
BioCryst's financial performance for Q1 2020 was detailed, highlighting revenue and expenses, along with program updates and key milestones.
Key Takeaways
BioCryst reported a decrease in total revenues to $4.8 million compared to $5.9 million in the first quarter of 2019. The net loss for the quarter was $37.6 million, or $0.24 per share, compared to a net loss of $31.1 million, or $0.28 per share, for the first quarter of 2019. The company's cash, cash equivalents, and investments totaled $114.6 million at the end of March 2020.
Berotralstat approval and launch timelines in the U.S., Japan, and EU remain on track.
Early clinical data supports BCX9930 as an oral monotherapy for complement-mediated diseases.
Patient dosing is underway in the galidesivir trial for COVID-19 patients in Brazil.
Company prepares to launch berotralstat in multiple territories to bring their oral, once-daily prophylactic medicine to HAE patients.
Forward Guidance
BioCryst expects full year 2020 net operating cash use to be in the range of $125 to $150 million, and its operating expenses to be in the range of $135 to $160 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...